MeiraGTx scoops up to $400M from Oberland Capital to push gene therapies toward commercialization

MeiraGTx has secured up to $400 million in funding from Oberland Capital Management to support the development and commercialization of its late-stage gene therapy programs.

The deal includes up to $375 million in non-dilutive royalty-based financing and up to $25 million in equity investment by Oberland.

The capital will largely support the potential commercialization of two gene therapies:
bota-vec (botaretigene sparoparvovec) for X‑linked retinitis pigmentosa and AAV2‑hAQP1 for radiation‑induced xerostomia.

AAV2‑hAQP1 data from a pivotal study are expected in the second quarter of 2027, with U.S. approval targeted in 2027 and a potential launch as early as 2028, helped by priority review eligibility.

In exchange, Oberland receives capped, low‑single‑digit royalties on global net sales of three MeiraGTx assets (bota-vec, AAV2‑hAQP1, and AAV‑AIPL1 for Leber congenital amaurosis‑4), secured by senior liens over the company’s cash, receivables, and product‑related assets.